Download PDF
Thromb Haemost 2012; 108(01): 176-182
DOI: 10.1160/TH12-02-0059
New Technologies, Diagnostic Tools and Drugs
Schattauer GmbH

Lyophilised reconstituted human platelets increase thrombus formation in a clinical ex vivo model of deep arterial injury

Nikhil Vilas Joshi
1   Centre for Cardiovascular Sciences, University of Edinburgh, UK
,
Jennifer B. Raftis
2   Centre for Inflammation Research, University of Edinburgh, UK
,
Andrew J. Lucking
1   Centre for Cardiovascular Sciences, University of Edinburgh, UK
,
Amanda H. Hunter
1   Centre for Cardiovascular Sciences, University of Edinburgh, UK
,
Mike Millar
3   Centre for Reproductive Health, University of Edinburgh, UK
,
Mike Fitzpatrick
4   Cellphire INC., Rockville, Maryland, USA
,
Giora Z. Feuerstein
4   Cellphire INC., Rockville, Maryland, USA
,
David E. Newby
1   Centre for Cardiovascular Sciences, University of Edinburgh, UK
› Author Affiliations Financial support: The study was supported by an unrestricted research grant by Cellphire Inc. NVJ is supported by Chief Scientist Office (ETM/160) and BMA's Josephine Lansdell Award (2011).
Further Information

Publication History

Received: 01 February 2012

Accepted after major revision: 01 April 2012

Publication Date:
22 November 2017 (online)

    Permissions and Reprints

Summary

Platelets are the principal component of the innate haemostatic system that protect from traumatic bleeding. We investigated whether lyophilised human platelets (LHPs) could enhance clot formation within platelet-free and whole blood environments using an ex vivo model of deep arterial injury. Lyophilised human platelets were produced from stored human platelets and characterised using conventional, fluorescent and electron microscopic techniques. LHPs were resuspended in platelet-free plasma (PFP) obtained from citrated whole human blood to form final concentrations of 0,20 and 200 × 109 LHPs/L. LHPs with recalcified PFP or whole blood were perfused through the chamber at low (212 s-1) and high (1,690 s-1) shear rates with porcine aortic tunica media as thrombogenic substrate. LHPs shared morphological characteristics with native human platelets and were incorporated into clot generated from PFP or whole blood. Histomorphometrically measured mean thrombus area increased in a dose-dependent manner following the addition of LHPs to PFP under conditions of high shear [704 μm2 ± 186 μm2 (mean ± SEM), 1,511 μm2 ± 320 μm2 and 2,378 μm2 ± 315 μm2, for LHPs at 0, 20 and 200 × 109 /l, respectively (p= 0.012)]. Lyophil-ised human platelets retain haemostatic properties when reconstituted in both PFP and whole blood, and enhance thrombus formation in a model of deep arterial injury. These data suggest that LHPs have the potential to serve as a therapeutic intervention during haemorrhage under circumstances of trauma, and platelet depletion or dysfunction.

Keywords

Bleeding disorders - haemostasis - lyophilised human platelets - platelet substitutes
 

  • References

  • 1 Stroncek DF, Rebulla P. Platelet transfusions. Lancet 2007; 370: 427-438.
    CrossrefPubMedGoogle Scholar
  • 2 Blajchman M. Substitutes and alternatives to platelet transfusions in thrombocytopenic patients. J Thromb Haemost 2003; 01: 1637-1641.
    CrossrefPubMedGoogle Scholar
  • 3 Holme S, Heaton A. In vitro platelet ageing at 22 degrees C is reduced compared to in vivo ageing at 37 degrees C. Br J Haematol 1995; 91: 212-218.
    CrossrefPubMedGoogle Scholar
  • 4 Sauaia A, Moore FA, Moore EE. et al. Epidemiology of trauma deaths: a reassessment. J Trauma 1995; 38: 185-193.
    CrossrefPubMedGoogle Scholar
  • 5 Holcomb JB, McMullin NR, Pearse L. et al. Causes of death in U.S. Special Operations Forces in the global war on terrorism: 2001-2004.. Ann Surg 2007; 245: 986-991.
    CrossrefPubMedGoogle Scholar
  • 6 Heal JM, Blumberg N. Optimizing platelet transfusion therapy. Blood Rev 2004; 18: 149-165.
    CrossrefPubMedGoogle Scholar
  • 7 Blajchman MA. Novel platelet products, substitutes and alternatives. Transfus Clin Biol 2001; 08: 267-271.
    CrossrefPubMedGoogle Scholar
  • 8 Bode AP, Fischer TH. Lyophilized platelets: fifty years in the making. Artif Cells Blood Substit Immobil Biotechnol 2007; 35: 125-133.
    CrossrefPubMedGoogle Scholar
  • 9 Fitzpatrick G, Agashe H, Dee J. Trehalose stabilized freeze dried human platelets, Thrombosomes, reduce blood loss in thrombocytopenic rabbit ear bleed model by as much as 89.5%. International Society of Blood Transfusion. Vox Sanguinis. 2010 99. (Suppl 1): Abstract P-0452.
    PubMedGoogle Scholar
  • 10 Fitzpatrick M, Dee J, Koh A. et al. Characterization of a novel lyophilized platelet derivative (LPDH) which exhibits in vitro hemostatic function, and in vivo safety and efficacy in trauma induced uncontrolled bleeding in nonhuman primate. ASH Annual Meeting Abstracts 2011. Blood. 2011 118. Abstract 719.
    PubMedGoogle Scholar
  • 11 Zafar MU, Farkouh ME, Osende J. et al. Potent arterial antithrombotic effect of direct factor-Xa inhibition with ZK-807834 administered to coronary artery disease patients. Thromb Haemost 2007; 97: 487-492.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Wahlander K, Eriksson-Lepkowska M, Nystrom P. et al. Antithrombotic effects of ximelagatran plus acetylsalicylic acid (ASA) and clopidogrel plus ASA in a human ex vivo arterial thrombosis model. Thromb Haemost 2006; 95: 447-453.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Lucking AJ, Chelliah R, Trotman AD. et al. Characterisation and reproducibility of a human ex vivo model of thrombosis. Thromb Res 2010; 126: 431-435.
    CrossrefPubMedGoogle Scholar
  • 14 Vilahur G, Pena E, Padro T. et al. Protein disulphide isomerase-mediated LA419- NO release prov ides additional ant ithrombotic effects to the blockade of the ADP receptor. Thromb Haemost 2007; 97: 650-657.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Chelliah R, Lucking A, Tattersall L. et al. P selectin antagonism reduces thrombus formation in humans. J Thromb Haemost 2009; 07: 1915-1919.
    CrossrefPubMedGoogle Scholar
  • 16 Lucking A, Visvanathan A, Philippou H. et al. Effect of the small molecule plasminogen activator inhibitor 1 (PAI 1) inhibitor, PAI 749, in clinical models of fibrinolysis. J Thromb Haemost 2010; 08: 1333-1339.
    CrossrefPubMedGoogle Scholar
  • 17 Lucking AJ, Lundback M, Mills NL. et al. Diesel exhaust inhalation increases thrombus formation in man. Eur Heart J 2008; 29: 3043-3051.
    CrossrefPubMedGoogle Scholar
  • 18 Read MS, Reddick RL, Bode AP. et al. Preservation of hemostatic and structural properties of rehydrated lyophilized platelets: potential for long-term storage of dried platelets for transfusion. Proc Natl Acad Sci USA 1995; 92: 397-401.
    CrossrefPubMedGoogle Scholar
  • 19 Read MS, Bode AP. Platelet storage: efforts to extend the shelf life of platelet concentrates. Mol Med Today 1995; 01: 322-328.
    CrossrefPubMedGoogle Scholar
  • 20 Hawksworth J, Elster E, Fryer D. et al. Evaluation of lyophilized platelets as an infusible hemostatic agent in experimental non compressible hemorrhage in swine. J Thromb Haemost 2009; 07: 1663-1671.
    CrossrefPubMedGoogle Scholar
  • 21 Bode A, Blajchman M, Bardossy L. et al. Hemostatic properties of human lyophil-ized platelets in a thrombocytopenic rabbit model and a simulated bleeding time device. Blood 1994; 84 (Suppl. 01) 464a.
    PubMedGoogle Scholar
  • 22 Bode AP, Read MS, Reddick RL. Activation and adherence of lyophilized human platelets on canine vessel strips in the Baumgartner perfusion chamber* 1,* 2,* 3. J Lab Clin Med 1999; 133: 200-211.
    CrossrefPubMedGoogle Scholar
  • 23 Valeri C, MacGregor H, Barnard M. et al. Survival of baboon biotin X N hydroxy-succinimide and 111In oxine labelled autologous fresh and lyophilized reconstituted platelets. Vox Sang 2005; 88: 122-129.
    CrossrefPubMedGoogle Scholar
  • 24 Blajchman MA. Substitutes for success. Nat Med 1999; 05: 17-18.
    CrossrefPubMedGoogle Scholar
  • 25 Lee DH, Blajchman MA. Novel platelet products and substitutes. Transfus Med Rev 1998; 12: 175-187.
    CrossrefPubMedGoogle Scholar
  • 26 Dangas G, Badimon JJ, Coller BS. et al. Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition: implications for a potential anticoagulant effect of abciximab. Arterioscl Thromb Vasc Biol 1998; 18: 1342.
    CrossrefPubMedGoogle Scholar
  • 27 Fischer TH, Merricks EP, Bode AP. et al. Thrombus formation with rehydrated, lyophilized platelets. Hematology 2002; 07: 359-369.
    CrossrefPubMedGoogle Scholar
  • 28 Bode AP, Read MS. Lyophilized platelets: continued development. Transfusion Sci 2000; 22: 99-105.
    PubMedGoogle Scholar